# Proof Launches California’s First 100% Legal Cannabis Pet Product > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-pet-products-safety-legal-tested-options/ > **Published:** 2026-03-10T07:07:29-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:09:44-04:00 > **Clinical Summary:** Explore cannabis pet products safety with pharmaceutical-grade testing and legal standards for pets’ pain and anxiety relief. --- ✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. CBDSafetyIndustry Why This Matters Clinicians should be aware that cannabis pet products are entering the legal market with pharmaceutical-grade testing standards, which means patients may increasingly ask about cannabinoid use for their pets’ pain, anxiety, or other conditions. Understanding the evidence base and regulatory status of these products will help clinicians provide informed guidance on safety, efficacy, and drug interactions, particularly since pets may have different [cannabinoid metabolism](https://cedclinic.com/fatty-acid-amide-hydrolase-obesity-risk-genetic-links/) than humans. As the pet cannabis market expands with legal products, clinicians should stay current on emerging research about [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) function in animals to counsel patients appropriately about risks and benefits. Clinical Summary Proof has launched a cannabis-derived pet product in California that undergoes pharmaceutical-grade testing and quality assurance, recognizing that companion animals possess endocannabinoid systems similar to humans. The product represents a regulated alternative to unvetted pet cannabis formulations currently available in the market, addressing concerns about product safety, potency accuracy, and contaminant exposure in animals. As more pet owners explore cannabis for conditions such as pain, anxiety, and seizures in dogs and cats, the availability of standardized, tested products may reduce risks associated with inconsistent dosing or contaminated preparations. Clinicians should be aware that pet owners may inquire about cannabis use in their animals or present with pets showing adverse effects from unregulated products, making knowledge of available regulated options relevant to veterinary and even primary care discussions about household exposures. The practical takeaway is that clinicians should ask pet-owning patients about cannabis product use in their animals and recommend regulated, tested formulations over unvetted alternatives when patients express interest in this therapeutic approach. Dr. Caplan’s Take “The [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) in animals functions similarly to humans, which means we should approach cannabis products for pets with the same clinical rigor we apply to human medicine, including third-party testing and dose standardization, rather than treating them as an unregulated supplement category.” Clinical Perspective While the emerging market for cannabis products in pets reflects genuine scientific interest in the endocannabinoid system shared across mammalian species, veterinarians should approach these products with appropriate caution given the limited rigorous clinical evidence in animal populations. Current pet cannabis products lack the robust safety and efficacy data standard for veterinary pharmaceuticals, and state-level regulation of cannabis products—even those marketed as “100% legal”—does not guarantee the same quality oversight or clinical validation that pharmaceutical-grade medications receive. Confounding factors such as placebo effects in owner-perceived outcomes, variable cannabinoid concentrations across products, and the potential for drug interactions with conventional medications remain inadequately characterized in veterinary medicine. When clients inquire about [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/) for their pets’ pain, anxiety, or other conditions, clinicians should acknowledge the biological plausibility of endocannabinoid system involvement while honestly discussing the evidence gap, documenting 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Proof+Launches+California%27s+First+100%25+Legal+Cannabis+Pet+Product+%40drcaplan&url=https%3A%2F%2Fnatlawreview.com%2Fpress-releases%2Fproof-launches-californias-first-100-legal-cannabis-pet-product) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fnatlawreview.com%2Fpress-releases%2Fproof-launches-californias-first-100-legal-cannabis-pet-product) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Proof+Launches+California%27s+First+100%25+Legal+Cannabis+Pet+Product+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fnatlawreview.com%2Fpress-releases%2Fproof-launches-californias-first-100-legal-cannabis-pet-product) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [In the Mix: 9 More Articles — March 10, 2026](https://cedclinic.com/cannabis-regulatory-landscape-2026/) 📰 Source: [https://natlawreview.com/press-releases/proof-launches-californias-first-100-legal-cannabis-pet-product](https://natlawreview.com/press-releases/proof-launches-californias-first-100-legal-cannabis-pet-product) Further Reading Cannabis Policy Wire[Policy Watch: 20 Regulatory Updates — March 10, 2026](https://cedclinic.com/dea-scheduling-synthetic-opioids-regulatory-updates-2026/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Research Digest[Daily Digest 2026-03-07](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Mom's homemade medical cannabis recipe now being sold at Ga. dispensaries – WRDW](https://cedclinic.com/patient-derived-cannabis-formulations-georgia/) Learn about grassroots cannabis product development and its transition into regulated dispensaries, highlighting safety and quality standards. [Read More](https://cedclinic.com/patient-derived-cannabis-formulations-georgia/) [Cannabis testing challenges persist as Virginia retail market nears | State News – CBS19](https://cedclinic.com/virginia-cannabis-testing-challenges-retail-market/) Explore ongoing challenges in cannabis product testing and quality assurance as legal markets expand, relevant to pet product safety. [Learn More](https://cedclinic.com/virginia-cannabis-testing-challenges-retail-market/) [Exploring Cannabinoids and Their Role in Patient Care – Cannabis News | NUG Magazine](https://cedclinic.com/cannabinoid-therapeutics-clinical-practice-patient-care/) An educational overview of cannabinoids’ therapeutic potential and safety considerations, applicable to both human and veterinary contexts. [Explore Now](https://cedclinic.com/cannabinoid-therapeutics-clinical-practice-patient-care/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).